Protalix BioTherapeutics Crescita futura
Future criteri di controllo 5/6
Protalix BioTherapeutics is forecast to grow earnings and revenue by 106.9% and 57.6% per annum respectively while EPS is expected to grow by 106.5% per annum.
Informazioni chiave
106.9%
Tasso di crescita degli utili
106.5%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 36.4% |
| Tasso di crescita dei ricavi | 57.6% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 22 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 167 | 100 | N/A | N/A | 1 |
| 12/31/2025 | 101 | 54 | N/A | N/A | 1 |
| 12/31/2024 | 54 | 5 | N/A | N/A | 1 |
| 6/30/2024 | 38 | -15 | -4 | -3 | N/A |
| 3/31/2024 | 60 | 7 | 4 | 6 | N/A |
| 12/31/2023 | 65 | 8 | -2 | -1 | N/A |
| 9/30/2023 | 64 | 11 | -9 | -8 | N/A |
| 6/30/2023 | 67 | 9 | -11 | -10 | N/A |
| 3/31/2023 | 41 | -16 | -23 | -22 | N/A |
| 12/31/2022 | 48 | -15 | -26 | -25 | N/A |
| 9/30/2022 | 48 | -18 | -28 | -27 | N/A |
| 6/30/2022 | 45 | -18 | -21 | -20 | N/A |
| 3/31/2022 | 43 | -24 | -8 | -6 | N/A |
| 12/31/2021 | 38 | -28 | -12 | -10 | N/A |
| 9/30/2021 | 49 | -21 | -14 | -13 | N/A |
| 6/30/2021 | 48 | -21 | -16 | -14 | N/A |
| 3/31/2021 | 53 | -14 | -30 | -29 | N/A |
| 12/31/2020 | 63 | -7 | -27 | -26 | N/A |
| 9/30/2020 | 61 | -7 | -23 | -22 | N/A |
| 6/30/2020 | 65 | -6 | -23 | -22 | N/A |
| 3/31/2020 | 66 | -9 | -20 | -19 | N/A |
| 12/31/2019 | 55 | -18 | -20 | -19 | N/A |
| 9/30/2019 | 47 | -24 | -20 | -20 | N/A |
| 6/30/2019 | 45 | -26 | -3 | -3 | N/A |
| 3/31/2019 | 38 | -26 | -6 | -6 | N/A |
| 12/31/2018 | 34 | -26 | -8 | -8 | N/A |
| 9/30/2018 | 28 | -34 | 13 | 14 | N/A |
| 6/30/2018 | 23 | -40 | -11 | -10 | N/A |
| 3/31/2018 | 25 | -32 | N/A | -11 | N/A |
| 12/31/2017 | 21 | -83 | N/A | -10 | N/A |
| 9/30/2017 | 19 | -73 | N/A | -35 | N/A |
| 6/30/2017 | 16 | -69 | N/A | -28 | N/A |
| 3/31/2017 | 11 | -80 | N/A | -31 | N/A |
| 12/31/2016 | 9 | -29 | N/A | -32 | N/A |
| 9/30/2016 | 7 | -35 | N/A | -29 | N/A |
| 6/30/2016 | 4 | -34 | N/A | -34 | N/A |
| 3/31/2016 | 3 | -29 | N/A | -27 | N/A |
| 12/31/2015 | 4 | -27 | N/A | -24 | N/A |
| 9/30/2015 | -6 | -31 | N/A | -25 | N/A |
| 6/30/2015 | -4 | -33 | N/A | -26 | N/A |
| 3/31/2015 | -2 | -32 | N/A | -27 | N/A |
| 12/31/2014 | 4 | -33 | N/A | -29 | N/A |
| 9/30/2014 | 15 | -32 | N/A | -29 | N/A |
| 6/30/2014 | 15 | -30 | N/A | -28 | N/A |
| 3/31/2014 | 15 | -31 | N/A | -29 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: PBDA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Guadagni vs Mercato: PBDA is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: PBDA is expected to become profitable in the next 3 years.
Ricavi vs Mercato: PBDA's revenue (57.6% per year) is forecast to grow faster than the German market (5.5% per year).
Ricavi ad alta crescita: PBDA's revenue (57.6% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if PBDA's Return on Equity is forecast to be high in 3 years time